Search filters

Filters
Clear All

Phase

  • 33
  • 92
  • 1
  • 77
  • 37
  • 1
  • 93
  • 357
  • 158
  • 13
  • 16
  • 328
  • 354
  • 3

Found 357 Neoplasms trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 A Study of DCC-3116 as Monotherapy and Combination Therapy in Patients With MAPK Pathway Mutant Solid Tumors
18 years - 99 years
All genders
Phase 1
Interventional
This is a Phase 1/2, multicenter, open label, study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
 METAMORPH
99 years or below
All genders
This is a cohort study of women with suspected or confirmed recurrent breast cancer, with accessible tumor by standard clinical biopsy, prior to starting a new therapy for recurrent metastatic disease. Study participants will be ascertained from the population of all persons greater than eighteen years of age receiving care …
 Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Na ve Metastatic Anal Cancer Patients
18 years - 99 years
All genders
Interventional
This trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor …
18 years - 99 years
All genders
Phase 1
Interventional
The purpose of this research study is to: • Test how safe RP-6306 and gemcitabine are when given together at different doses and on different schedules • Test how well RP-6306 and gemcitabine work together to shrink cancer in the body RP-6306 is a PKMYT1 inhibitor that is designed to …
 Genetics and Heart Health after Cancer Therapy
99 years or below
All genders
The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease. We plan to enroll 100 BRCA1/2 mutation carriers who have been treated for …
 SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 multi-institution randomized prospective clinical trial evaluating the impact of cytoreductive radical prostatectomy combined with best systemic therapy on oncologic and quality of life outcomes in men with newly diagnosed metastatic prostate cancer
18 years - 100 years
All genders
Phase 2
This study investigates the effects of adding cytoreductive radical prostatectomy (CRP) to the standard treatment, best systemic therapy (BST), for metastatic prostate cancer (mPCa). CRP removes as much of the cancer as possible (and radical prostatectomy removes only prostate) while BST uses drugs toxic to cancer cells: chemotherapy and androgen …
 A Randomized Multicenter Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
18 years - 98 years
All genders
Phase 2
The BBI-DSP-7888-201G trial is designed to compare the overall survival (OS) between treatment with DSP-7888 Dosing Emulsion plus bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following initial therapy. This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study. Approximately 200 patients …
 Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
18 years - 99 years
All genders
Phase 1
Interventional
This research study consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be …
251 - 260 of 357